LLY

984.02

-1.85%↓

JNJ

201.6

-1.57%↓

ABBV

222.42

-0.37%↓

UNH

322.88

-0.38%↓

AZN

90.6

-0.22%↓

LLY

984.02

-1.85%↓

JNJ

201.6

-1.57%↓

ABBV

222.42

-0.37%↓

UNH

322.88

-0.38%↓

AZN

90.6

-0.22%↓

LLY

984.02

-1.85%↓

JNJ

201.6

-1.57%↓

ABBV

222.42

-0.37%↓

UNH

322.88

-0.38%↓

AZN

90.6

-0.22%↓

LLY

984.02

-1.85%↓

JNJ

201.6

-1.57%↓

ABBV

222.42

-0.37%↓

UNH

322.88

-0.38%↓

AZN

90.6

-0.22%↓

LLY

984.02

-1.85%↓

JNJ

201.6

-1.57%↓

ABBV

222.42

-0.37%↓

UNH

322.88

-0.38%↓

AZN

90.6

-0.22%↓

Home・Aktien・Cassava Sciences Inc

Cassava Sciences Inc

Geschlossen

BrancheGesundheitswesen

3.25 1.56

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.14

Max

3.27

Schlüsselkennzahlen
By Trading Economics
Einkommen	33M -11M
Verkäufe	840K 840K
EPS	-0.22
Gewinnspanne	-1,286.548
Angestellte	30
EBITDA	35M -11M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+150% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-4.3M 142M
Vorheriger Eröffnungskurs	1.69
Vorheriger Schlusskurs	3.25

Nachrichtenstimmung

By Acuity

50%

182 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

1.56 / 1.7 Unterstützung & Widerstand

Cassava Sciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Dez. 2025, 22:13 UTC

Ergebnisse

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9. Dez. 2025, 21:40 UTC

Ergebnisse

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9. Dez. 2025, 18:51 UTC

Akquisitionen, Fusionen, Übernahmen

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9. Dez. 2025, 16:57 UTC

Wichtige Markttreiber

Clear Secure Rises on Medicare Identity Verification Contract

9. Dez. 2025, 23:46 UTC

Market Talk

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9. Dez. 2025, 23:46 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings Stake in Lenovo Now at 32.34%

9. Dez. 2025, 23:45 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9. Dez. 2025, 23:44 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9. Dez. 2025, 23:43 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9. Dez. 2025, 23:43 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9. Dez. 2025, 23:35 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9. Dez. 2025, 22:42 UTC

Ergebnisse

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9. Dez. 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Dez. 2025, 21:48 UTC

Market Talk

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9. Dez. 2025, 20:28 UTC

Market Talk

Oil Futures Decline for Second Straight Session -- Market Talk

9. Dez. 2025, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9. Dez. 2025, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Teck Reports Voting Results From Special Meeting of Hldrs

9. Dez. 2025, 20:26 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9. Dez. 2025, 20:21 UTC

Market Talk

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9. Dez. 2025, 19:52 UTC

Ergebnisse

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9. Dez. 2025, 19:17 UTC

Ergebnisse

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9. Dez. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Dez. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. Dez. 2025, 17:11 UTC

Ergebnisse

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Peer-Vergleich

Kursveränderung

Cassava Sciences Inc Prognose

Kursziel

By TipRanks

150% Vorteil

12-Monats-Prognose

Durchschnitt 8 USD 150%

Hoch 8 USD

Tief 8 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cassava Sciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cassava Sciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.56 / 1.7Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Stimmung

By Acuity

182 / 374 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.